Epitalon Peptide Extended Lifespan by 12% and Reduced Cancer in Aging Mice
Monthly injections of the tetrapeptide Epitalon increased both mean and maximum lifespan by 12.3% in female mice while reducing malignant lymphoma incidence and slowing age-related decline.
Quick Facts
What This Study Found
Subcutaneous Epitalon injections (0.1 µg per mouse, 5 consecutive days per month starting at 3 months of age) in female SHR mice increased both mean and maximum lifespan by 12.3% compared to untreated controls.
The peptide did not increase total spontaneous tumor incidence but significantly decreased the incidence of malignant lymphomas. Additionally, Epitalon preserved estrous cycle function longer, slowed age-related deterioration of immune parameters, and reduced the frequency of chromosome aberrations in bone marrow cells of old mice.
Key Numbers
How They Did This
Female Swiss-derived SHR mice received subcutaneous injections of Epitalon (Ala-Glu-Asp-Gly) at 0.1 µg per mouse for 5 consecutive days each month, beginning at age 3 months and continuing through life. Controls received no treatment. Outcomes measured included lifespan, spontaneous tumor incidence, estrous cycle function, immune parameters, and chromosome aberration frequency in bone marrow cells.
Why This Research Matters
Epitalon is one of the Khavinson peptide bioregulators — short synthetic peptides developed in Russia as potential anti-aging interventions. This study is frequently cited in longevity research because it shows a single, very small peptide simultaneously affecting multiple aging biomarkers: lifespan, cancer incidence, reproductive aging, immune function, and chromosomal stability. If these results translate beyond mice, the implications for aging biology would be significant.
The Bigger Picture
Epitalon belongs to a class of short peptide bioregulators championed by Russian gerontologist Vladimir Khavinson. This study is one of several from Anisimov and Khavinson's group showing lifespan extension in rodents with these tetrapeptides. While the results are intriguing, this line of research has remained largely within the Russian scientific community, with limited independent replication by Western labs — a gap that leaves the findings promising but incompletely validated.
What This Study Doesn't Tell Us
This is a single-lab study from the Khavinson/Anisimov research group, which has not been independently replicated by other laboratories. The SHR mouse strain is specific and may not represent general aging biology. The abstract does not report group sizes, making it difficult to assess statistical power. The extremely low dose (0.1 µg) raises questions about mechanism and bioavailability. No human studies of Epitalon for lifespan extension exist.
Questions This Raises
- ?Has any independent laboratory replicated Epitalon's lifespan extension effects in mice or other organisms?
- ?What is Epitalon's proposed mechanism of action — does it work through telomerase activation, pineal gland function, or another pathway?
- ?Would these effects be seen in male mice or in other mouse strains with different aging and cancer profiles?
Trust & Context
- Key Stat:
- 12.3% lifespan extension Both mean and maximum lifespan increased by 12.3% in female mice receiving monthly Epitalon courses from age 3 months
- Evidence Grade:
- This is a preclinical animal study from a single research group (Anisimov/Khavinson) that has not been independently replicated. While the study design is reasonable, the lack of independent confirmation and the absence of human data place the evidence at a low level for clinical applicability.
- Study Age:
- Published in 2003, this study is over two decades old. It remains one of the most-cited Epitalon studies, but the lack of subsequent independent replication or human trials limits how much weight should be placed on it.
- Original Title:
- Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.
- Published In:
- Biogerontology, 4(4), 193-202 (2003)
- Authors:
- Anisimov, V N, Khavinson, V Kh(3), Popovich, I G, Zabezhinski, M A, Alimova, I N, Rosenfeld, S V, Zavarzina, N Yu, Semenchenko, A V, Yashin, A I
- Database ID:
- RPEP-00788
Evidence Hierarchy
Frequently Asked Questions
What is Epitalon and how is it supposed to work?
Epitalon (also spelled Epithalon) is a synthetic tetrapeptide (Ala-Glu-Asp-Gly) developed by Russian scientist Vladimir Khavinson. It's proposed to work by stimulating telomerase production in the pineal gland, potentially slowing cellular aging. However, its exact mechanism remains debated and incompletely characterized.
Can people take Epitalon to live longer?
There are no human clinical trials demonstrating that Epitalon extends human lifespan. While this mouse study is interesting, results from a single lab in one mouse strain cannot be directly applied to humans. Epitalon is sold as a research peptide but is not approved for any medical use.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-00788APA
Anisimov, V N; Khavinson, V Kh; Popovich, I G; Zabezhinski, M A; Alimova, I N; Rosenfeld, S V; Zavarzina, N Yu; Semenchenko, A V; Yashin, A I. (2003). Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.. Biogerontology, 4(4), 193-202. https://doi.org/10.1023/A:1025114230714
MLA
Anisimov, V N, et al. "Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice.." Biogerontology, 2003. https://doi.org/10.1023/A:1025114230714
RethinkPeptides
RethinkPeptides Research Database. "Effect of Epitalon on biomarkers of aging, life span and spo..." RPEP-00788. Retrieved from https://rethinkpeptides.com/research/anisimov-2003-effect-of-epitalon-on-biomarkers
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.